Vivek Subbiah

Associate Professor

  • 3227 Citations
  • 28 h-Index
If you made any changes in Pure, your changes will be visible here soon.

Fingerprint Dive into the research topics where Vivek Subbiah is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 10 Similar Profiles
Neoplasms Medicine & Life Sciences
Therapeutics Medicine & Life Sciences
Sarcoma Medicine & Life Sciences
Mutation Medicine & Life Sciences
Clinical Trials, Phase I Medicine & Life Sciences
Ewing's Sarcoma Medicine & Life Sciences
Antineoplastic Combined Chemotherapy Protocols Medicine & Life Sciences
Sirolimus Medicine & Life Sciences

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output 2007 2019

3 Citations (Scopus)

Alpha particle radium 223 dichloride in high-risk osteosarcoma: A phase i dose escalation trial

Subbiah, V., Anderson, P. M., Kairemo, K., Hess, K. R., Huh, W., Ravi, V., Daw Bitar, N., Somaiah, N., Ludwig, J. A., Benjamin, R. S., Chawla, S., Hong, D. S., Meric-Bernstam, F., Ravizzini, G., Kleinerman, E. S., Macapinlac, H. A. & Rohren, E., Jan 1 2019, In : Clinical Cancer Research. 25, 13, p. 3802-3810 9 p.

Research output: Contribution to journalArticle

Open Access
Alpha Particles
Neoplasm Metastasis
Technetium Tc 99m Medronate
2 Citations (Scopus)

Analysis of cell-free DNA from 32,989 advanced cancers reveals novel co-occurring activating RET alterations and oncogenic signaling pathway aberrations

Rich, T. A., Reckamp, K. L., Chae, Y. K., Doebele, R. C., Iams, W. T., Oh, M., Raymond, V. M., Lanman, R. B., Riess, J. W., Stinchcombe, T. E., Subbiah, V., Trevarthen, D. R., Fairclough, S., Yen, J. & Gautschi, O., Jan 1 2019, In : Clinical Cancer Research. 25, 19, p. 5832-5842 11 p.

Research output: Contribution to journalArticle

Open Access
Gene Fusion
Circulating Neoplastic Cells
Phase II Clinical Trials
2 Citations (Scopus)

A phase i trial of the VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced solid tumors and differentiated thyroid cancers

Kurzrock, R., Ball, D. W., Zahurak, M. L., Nelkin, B. D., Subbiah, V., Ahmed, S., O'Connor, A., Karunsena, E., Parkinson, R. M., Bishop, J. A., Ha, Y., Sharma, R., Gocke, C. D., Zinner, R., Rudek, M. A., Sherman, S. I. & Azad, N. S., Sep 15 2019, In : Clinical Cancer Research. 25, 18, p. 5475-5484 10 p.

Research output: Contribution to journalArticle

Vascular Endothelial Growth Factor Receptor
Mitogen-Activated Protein Kinase Kinases
Thyroid Neoplasms
Protein-Tyrosine Kinases

Artificial Intelligence Systems Assisting Oncologists? Resist and Desist or Enlist and Coexist

Adashek, J. J., Subbiah, I. M. & Subbiah, V., Oct 1 2019, In : Oncologist. 24, 10, p. 1291-1293 3 p.

Research output: Contribution to journalComment/debate

Artificial Intelligence
1 Citation (Scopus)

Beyond KRAS: Practical Molecular Targets in Pancreatic Adenocarcinoma

Grinshpun, A., Zarbiv, Y., Roszik, J., Subbiah, V. & Hubert, A., Jan 1 2019, In : Case Reports in Oncology. 12, 1, p. 7-13 7 p.

Research output: Contribution to journalArticle

Clinical Trials